Targeted modulation of transcription is necessary for understanding complex gene networks and has great potential for medical and industrial applications. Clustered regularly interspaced short palindromic repeats (CRISPR) is emerging as a powerful system for targeted genome activation and repression, in addition to its use in genome editing. This protocol describes how to design, construct, and experimentally validate the function of sequence-specific single guide RNAs (sgRNAs) for sequencespecific repression (CRISPRi) or activation (CRISPRa) of transcription in mammalian cells. In this technology, the CRISPR-associated protein Cas9 is catalytically deactivated (dCas9) to provide a general platform for RNA-guided DNA targeting of any locus in the genome. Fusion of dCas9 to effector domains with distinct regulatory functions enables stable and efficient transcriptional repression or activation in mammalian cells. Delivery of multiple sgRNAs further enables activation or repression of multiple genes. By using scaffold RNAs (scRNAs), different effectors can be recruited to different genes for simultaneous activation of some and repression of others. The CRISPRi and CRISPRa methods provide powerful tools for sequence-specific control of gene expression on a genome-wide scale to aid understanding gene functions and for engineering genetic regulatory systems.
• Sequencing primer: 5
′ -GAGGCTTAATGTGCGATAAAAGA-3 ′ This primer binds to the mouse U6 promoter and is used to confirm the generation of sgRNA expression constructs in Step 21.
• Target gene-specific primers for qRT-PCR (see Step 40)
QIAGEN Plasmid Midi Kit (QIAGEN 12143)
It is important to use an endotoxin-free midiprep kit when purifying plasmid DNA for better transfection efficiency into mammalian cells. 
METHOD
We have implemented a computational tool, termed CRISPR-ERA ("editing, repression, and activation") for automated design of sgRNAs for given mammalian organisms, such as mouse, rat, and human. The CRISPR-ERA algorithm aligns the designed sgRNA to the whole genome and reports potential off-target sites as defined by possession of fewer than three mismatches. The tool is freely available at http://CRISPR-ERA.stanford.edu. If using CRISPR-ERA, skip Steps 1-5 Q8 .
Selection of sgRNA Targets in the Genome 1. Determine the DNA sequence of the target gene using an available genome database-for example, the UCSC genome browser (Kent et al. 2002) . 2. Obtain annotation information of the target gene, including the location of the transcription start site (TSS). 3. Search for patterns of GN (19) NGG around the TSS, wherein GN (19) is the binding site of the sgRNA and NGG is the protospacer adjacent motif (PAM), which is required for efficient DNA binding of Streptococcus pyogenes Cas9.
Our sgRNA expression construct uses a mouse U6 promoter, which requires a G at the very 5 ′ end for effective transcription. Therefore, we search for GN (19) as the binding site of the sgRNA. If another promoter is used, it is likely that the first nucleotide will be different.
The recommended window of the target DNA is −50 to +300 bp relative to the TSS for CRISPR interference (CRISPRi) for gene repression, or −400 to −50 bp for CRISPR activation (CRISPRa). Usually, multiple sgRNA-binding sites within the target window of the gene need to be tested to define the most efficient targeting site for repression or activation.
Many mammalian genes possess transcript isoforms with different TSSs. In this case, different sgRNAs need to be designed for each transcript. Currently, there is no direct evidence that the activities of CRISPRi and CRISPRa are sensitive to the DNA strand or GC content ).
Design of sgRNA Sequences

4.
Ensure that the base-pairing sequence on the sgRNA is the reverse complement of the GN (19) sequence identified in Step 3 Q9 . The BLAST algorithm enables the specificity of sgRNA targeting in the genome to be analyzed when not using the CRISPR-ERA tool.
6. Generate the full-length sgRNA by appending GN (19) 3 ′ to the rest of the optimized sgRNA sequence (5 ′ -GN (19) GUUUAAGAGCUAUGCUGGAAACAGCATAGCAAGUUUAAAUAAGG CUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU-3 ′ ) (Chen et al. 2013) . 7. Confirm that the sgRNA sequence does not contain any transcription terminator sequence for the U6 promoter-that is, more than four consecutive uridines (U) (Paul et al. 2002 Q11 ) .
Preparation of sgRNA Expression Constructs Q12
8. Generate the sgRNA backbone by digesting the empty sgRNA expression vector with restriction enzymes BstXI and XhoI for 4-16 h at 37˚C according to the manufacturer's instructions. 9. Separate the digested sgRNA backbone products by electrophoresis through a 1% (w/v) agarose gel in 1× TAE buffer. Stain the gel with ethidium bromide, and visualize the bands using a digital gel imaging system. Compare the bands to those of a proper DNA ladder, and confirm that the band representing the sgRNA backbone DNA is~8 kb Q13 . 10. Gel-purify the sgRNA backbone DNA using a QIAquick Gel Extraction Kit according to the manufacturer's instructions. Store the DNA at −20˚C until use in Step 15 Q14 . 11. Perform PCR as follows, using primers that contain the 20-nt target sequences identified in Steps 1-3.
i. Assemble the following reaction (volumes shown are for one reaction) in a 0.2-mL PCR tube on ice Q15 . 0.5 µL empty sgRNA expression vector (undigested) as template (100 ng/µL) 2.5 µL Forward primer (sgRNA-F) (10 µM) 2.5 µL Reverse primer (sgRNA-R) (10 µM) 2 µL dNTPs (10 mM) 0.5 µL Phusion High-Fidelity Polymerase (2 U/µL) 42 µL Nuclease-free water 50 µL Total volume Q16
ii. Perform PCR with the following cycling conditions:
1 cycle 98˚C 30 sec 25 cycles 98˚C 10 sec 62˚C 30 sec 72˚C 10 sec 1 cycle 72˚C 5 min 1 cycle 4˚C Forever
12.
Confirm that the PCRs successfully amplified a~150-bp DNA product by separating 5 µL of the PCR products on a 1% agarose gel as in Step 9. 13. Add 1 µL of DpnI (20 U/µL) into each PCR and then incubate for 1 h at 37˚C Q17 . 14. Purify the PCRs using a QIAquick PCR Purification Kit by following the manufacturer's instructions. Store the DNA at −20˚C until use in Step 15.
15.
Measure the concentrations of the purified sgRNA backbone DNA (from Step 10) and PCR fragments (from Step 14) using a NanoDrop UV-Vis 8000 Spectrophotometer Q18 . 16. Ligate the PCR fragments to the sgRNA backbone DNA using an In-Fusion HD Cloning Kit. ii. Incubate the reaction for 15 min at 50˚C using a thermocycler.
iii. Place on ice for 5 min. Store at −20˚C until use in Step 17.
17. Transform chemically competent E. coli cells with the products of the ligation reactions. Follow the manufacturer's instructions for the E. coli cells. Spread transformed E. coli cells onto LB agar plates supplemented with 100 µg/mL carbenicillin. Incubate the plates overnight in a 37˚C incubator. 18. Transfer single colonies into 25-mm glass tubes containing 5 mL of LB medium supplemented with 100 µg/mL carbenicillin. For each colony, use a sterile pipette tip to touch the colony, and then swirl the tip in the LB medium to dissolve the colony. Incubate overnight in a 37˚C shaking incubator, swirling at 200 rpm. 19. Transfer 0.5 mL of bacterial culture into a 250-mL Erlenmeyer flask containing 50 mL of LB medium with 100 µg/mL carbenicillin. Incubate overnight in a 37˚C shaking incubator, swirling at 200 rpm. 20. Extract the plasmid DNA from the remaining 4.5 mL of bacterial culture using a QIAprep Spin
Miniprep Kit according to the manufacturer's instructions. 21. Send the extracted plasmid DNA for sequencing with the sequencing primer.
22.
After the plasmid is verified by sequencing, extract DNA from the 50-mL bacterial culture using a QIAGEN Plasmid Midi Kit according to the manufacturer's instructions. Store the DNA at −20˚C until use in Step 27.
Preparation of dCas9 Expression Vectors 23. Transform chemically competent E. coli cells with the dCas9 expression vectors appropriate for the experiment (CRISPRi or CRISPRa). Spread transformed E. coli cells onto LB agar plates supplemented with 100 µg/mL carbenicillin. Incubate the plates overnight in a 37˚C incubator. 24. Transfer a single colony into 50 mL of LB medium supplemented with 100 µg/mL carbenicillin.
Incubate overnight in a 37˚C shaking incubator, swirling at 200 rpm. 25. Extract DNA using a QIAGEN Plasmid Midi Kit according to the manufacturer's instructions.
Store the DNA at −20˚C until use in Step 27.
Packaging of dCas9 and sgRNA Expression Constructs into Lentiviral Particles
If more lentiviruses are required, scale up the cell numbers, DNA amounts, and transfection reagent volumes used here.
26. On the day before transfection, seed a six-well tissue-culture plate with 2-3 × 10 5 HEK293T cells in 2 mL of high-glucose DMEM containing 10% (v/v) FBS per well. Incubate overnight at 37˚C and 5% CO 2 .
HEK293T cells can be maintained in regular high-glucose DMEM medium supplemented with 10% (v/v) FBS, 100 U/mL streptomycin, and 100 µg/mL penicillin and regularly passaged using 0.05% (w/v) trypsin-EDTA. However, antibiotic-free DMEM is required during transfection and virus collection to achieve better efficiency Q19 .
Cite this protocol as Cold Spring Harb Protoc; doi:10.1101/pdb.prot090175 27. Twenty-four hours after plating the cells, prepare the transfection complexes as follows.
i. Combine the following DNA samples. ii. Add this 3-µg DNA mixture into 250 µL of Opti-MEM Reduced-Serum Medium in a microcentrifuge tube. Mix well by pipetting up and down. iii. Add 7.5 µL of Mirus TransIT-LT1 Transfection Reagent into the same tube. Mix well by pipetting up and down. iv. Allow transfection complexes to form for 30 min at room temperature.
28. (Optional) Remove 250 µL of medium from each well in the six-well plate Q20 . 29. Add the~250-µL mixture from Step 27.iv into one well in the six-well plate. Mix well by rocking the plate gently back and forth. Incubate for 24 h at 37˚C and 5% CO 2 .
Cells will begin producing viruses 24 h after transfection.
30.
After the 24-h incubation, replace the transfection medium with 2.5 mL of fresh DMEM with 10% FBS.
If the target cells to be infected have any additional medium requirements, replace the transfection medium with 2.5 mL of special growth medium for the target cells.
Use a sterile syringe to harvest the viral supernatant 24-48 h after medium replacement.
Filter the medium through a 0.45-µm syringe filter into a conical tube to avoid transferring HEK293T cells.
The total volume will be~2 mL after filtering. Lentiviral particles can be stored at 4˚C for up to 1 wk, or snapfrozen in liquid nitrogen and stored at −80˚C for several months. However, we recommend using the lentiviruses immediately after collection.
Transduction of Target Cells with dCas9 and sgRNA Lentiviral Particles
In the following, the use of HEK293T cells is given as an example. For other types of cells, modify the procedure (e.g., cell number and growth medium) as appropriate.
32. Sixteen hours before transduction, seed a six-well tissue-culture plate with 1.5-2 × 10 5 HEK293T cells in 2 mL of high-glucose DMEM supplemented with 10% FBS per well. Incubate at 37˚C and 5% CO 2 Q21 . 33. Replace the medium with 1 mL of DMEM containing 10% FBS and 1 mL of filtered viral supernatant. Incubate overnight at 37˚C and 5% CO 2 .
Depending on the virus titration, the viral supernatant can be diluted with growth medium for the target cells. Polybrene can be used to promote the infection efficiency with proper concentration; however, it is toxic for some types of cells, including HEK293T cells.
34.
Replace the viral supernatant with 2 mL of fresh DMEM with 10% FBS, and incubate for 48 h at 37˚C and 5% CO 2 .
Cells usually will express dCas9 protein 48 h after addition of lentiviruses. However, for repression experiments, we suggest collecting cells at least 72 h after infection to minimize the interference by preexisting target gene mRNA. If necessary, split the cells when they reach 80%-90% confluence before sorting.
35. Use a BD FACSAria II Cell Sorter to collect the cells.
• For the CRISPRi system, collect cells positive for both blue fluorescent protein (BFP) and mCherry.
The BFP-positive cells should express dCas9 protein, and mCherry-positive cells should express sgRNA.
• For the CRISPRa (dCas9-Suntag) system, collect cells that are positive for BFP, mCherry, and GFP.
The GFP-positive cells should express scFv-sfGFP-VP64 fusion protein.
36. Incubate the collected cells at 37˚C and 5% CO 2 .
After the cells are grown up, analyze the expression levels of target genes by qRT-PCR as described in Steps 37-40 Q22 .
Quantification of the Effects of CRISPRi or CRISPRa on Gene Expression in Target Cells
37. Extract total RNA from the cells infected using an RNeasy Plus Mini Kit according to the manufacturer's instructions.
Typically, 0.5-1 × 106 cells (50%-80% confluence of cells in one well in a six-well plate) are sufficient for total RNA extraction.
38. Measure the concentrations of the total RNA samples using a NanoDrop spectrophotometer.
39.
Synthesize cDNA using an iScript cDNA Synthesis Kit.
i. Set up the cDNA synthesis reaction. The amount of template cDNA can be scaled up or down according to the expression levels of the target genes in the cells. Housekeeping genes-for example, GAPDH, encoding glyceraldehyde-3-phosphate dehydrogenase-should be used as references.
ii. Run the following real-time PCR profile in a CFX96 Real-Time PCR Detection System. iii. Analyze the qRT-PCR data by standard methods to obtain the relative transcriptional expression levels of the target genes regulated by CRISPRi/a.
We use the 2 -ΔΔCt method to obtain the relative mRNA expression level of the CRISPRi or CRISPRa sample vs. a control sample, where ΔΔCt = ΔCt(CRISPRi/a sample)-ΔCt(control sample, e.g., nontargeting sgRNA sample), and where ΔCt(sample) = Ct(any sample)-Ct(endogenous housekeeping gene).
DISCUSSION
To date, several tools have been developed to functionally interrogate gene expression. RNAi has been shown to disrupt gene expression by triggering the degradation of target mRNAs (Chang et al. 2006) . However, the technique is somewhat limited in its application owing to off-target effects and through being restricted to cytosolic target mRNAs (Jackson et al. 2003; Adamson et al. 2012; Sigoillot et al. 2012) . Protein-based tools are difficult to be designed, cloned, and delivered into target cells. The complex programming and limited targeting sites also restrict the application of zinc-fingers and tools based on transcription-activator-like effectors (TALEs) for perturbing the expression of multiple genes. Loss-of-function approaches based on genome editing, such as CRISPR-Cas9, cause irreversible frameshift disruptions, cytotoxic double-stranded DNA breaks, and in-frame insertion-deletions (indels) arising from error-prone DNA repair. These can limit the ability of the CRISPR technique to completely disable the genes and noncoding RNA (Huang et al. 1996; Jackson 2002; Koike-Yusa et al. 2014; Shalem et al. 2014; Wang et al. 2014 Q24 ) . In contrast, RNA-guided DNA targeting of the dCas9 protein to a specific locus provides a programmable platform to modulate genome status while generating minimal off-target effects. Fusion of different effector domains to dCas9 enables transcriptional repression (CRISPRi) or activation (CRISPRa) of specific target genes. CRISPRi and CRISPRa enable inducible and reversible modulation of specific endogenous gene expression within an intact biological system. The modulation of the transcription of single or multiple genes can be specifically achieved by delivery of multiple sgRNAs Qi et al. 2013; Tanenbaum et al. 2014; Zalatan et al. 2015) . By using scRNA, transcriptional activation or repression of different target genes can be achieved simultaneously in the same cell (Zalatan et al. 2015) . Recently, CRISPRa has been used to effectively activate expression of target genes in plants and flies (Lin et al. 2015; Lowder et al. 2015) . Furthermore, Kleinstiver and colleagues have modified S. pyogenes Cas9 (spCas9) to recognize alternative PAM sequences (other than NGG) by using a selection-based approach in bacterial cells (Kleinstiver et al. 2015) . This provides researchers an expanded targetable sequence space in the genome for using CRISPR-dCas9. Thus, owing to its simplicity and flexibility, CRISPRi or CRISPRa can facilitate genome-scale perturbation of gene expression Konermann et al. 2015) .
However, the detailed mechanism underlying how CRISPRi and CRISPRa components interact with local transcriptional machinery and epigenetic factors is not well established. We usually design three to five sgRNAs for each target transcript and choose the best one for functional analysis. The reason why some of the designed sgRNAs have no function and why the efficiency of different designed sgRNAs varies is not clear. Knowledge of the mechanism would assist the efficiency of designing functional sgRNAs. Moreover, the spCas9 protein, which is widely used for transcriptional modulation, is a large molecule that is difficult to clone and package with the necessary regulatory elements into a size-restricted virus, such as the adeno-associated virus (AAV) that has been generally used for gene therapy. In contrast, the smaller ortholog Staphylococcus aureus Cas9 (saCas9) has been shown to edit the targets efficiently and to be compatible with the AAV system, which has also been engineered as a transcriptional activating system (SAM) Ran et al. 2015) . Currently, the gene-regulatory tools based on the S. aureus dCas9 are being developed for moreefficient transcriptional repression and activation. Thus, in summary, CRISPRi and CRISPRa based on different species of Cas9 or its homologs provide a versatile platform to manipulate and interrogate gene expression systematically. ). Cool to 60˚C and add carbenicillin (final concentration 100 µg/mL). Pour the medium into Petri dishes ( 25 mL per 100-mm plate). Store the LB plates at 4˚C; they will keep for at least 4 mo. In
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